The invention provides a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein the variables X, Y
1
-Y
5
, R
1
, R
2
, R
3
, R
4
, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
[EN] HSD17B13 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE HSD17B13 ET LEURS UTILISATIONS
申请人:METACRINE INC
公开号:WO2022072512A1
公开(公告)日:2022-04-07
Described herein are compounds that are HSD17B13 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with HSD17B13 activity.
An organic light emitting device is provided. The device has an anode, a cathode, and an emissive layer disposed between the anode and the cathode, the emissive layer further comprising an emissive material having the structure:
1
wherein each of the variables are defined herein.
The invention provides a compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1—Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
本发明提供了一种式 I 的化合物:
或其药学上可接受的盐,其中变量 X、Y1-Y5、R1、R2、R3、R4 和 Het 的含义如本文所述,以及含有此类化合物的组合物和使用此类化合物及组合物的方法。
[EN] HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QUE RÉCEPTEUR DE DÉCLENCHEMENT EXPRIMÉ SUR DES AGONISTES DE CELLULES MYÉLOÏDES 2 ET PROCÉDÉS D'UTILISATION